Superpower peptides available for pre-order. Get first access.

Peptide science

What is ARA-290 (cibinetide)?

ARA-290 (cibinetide) is an 11-amino-acid peptide from erythropoietin that targets the innate repair receptor. See Phase II data and FDA status.

Quick answer

ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the helix-B surface of erythropoietin, designed to activate the innate repair receptor without stimulating red blood cell production. Human data comes mostly from small Phase II trials, including a 38-person sarcoidosis trial and a 49-person type 2 diabetes trial, each lasting 28 days. As of November 2026, it is not FDA-approved.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

How ARA-290 works on the innate repair receptor

ARA-290 is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin (EPO) to activate the innate repair receptor without raising red blood cell production. In rodent and cell studies, ARA-290 did not stimulate red blood cell formation1. Cibinetide is the same compound4, also called pyroglutamate helix B surface peptide (pHBSP).

ARA-290 began with a finding that modified EPO molecules could protect nerve tissue in animal models5 without any blood-forming activity. Researchers then isolated an 11-amino-acid sequence1 from the water-facing surface of EPO's helix B. That sequence protected tissue in rodent models of stroke and kidney injury.

EPO protects tissue through a receptor that pairs the EPO receptor (EPOR) with the beta-common receptor6 (CD131). This complex is known as the innate repair receptor (IRR)7. Red blood cell production runs through a separate two-EPOR receptor, which is why high-dose EPO raises hematocrit and blood clot risk7.

The innate repair receptor is usually missing from healthy tissue and appears with inflammation or low oxygen after injury8. Other receptors may also take part in some tissues.

In rats with nerve injury, a short course of ARA-290 eased pain-like sensitivity for up to 20 weeks9 and quieted spinal immune cells. Cell and rodent tests suggest ARA-290 may block TRPV110, a pain-sensing channel on nerve endings. ARA-290 was then tested in people with nerve damage.

What ARA-290 human trials have found

ARA-290's human evidence stops at small Phase II trials in sarcoidosis-related small-fiber neuropathy and type 2 diabetes, with no Phase III trial completed. Those trials linked ARA-290 to corneal nerve fiber gains in sarcoidosis and to better blood sugar control in diabetes.

Small-fiber neuropathy damages the thin nerve fibers that sense pain and temperature11. An eye scan called corneal confocal microscopy can count these fibers12. The condition affects an estimated 33% to 86% of people with sarcoidosis13.

In a 38-person placebo-controlled trial, 28 days of ARA-290 improved symptom scores and increased corneal nerve fiber density14. A 64-person Phase IIb trial found more corneal nerve fiber area15 at the middle of three doses. Pain eased in every group of that trial, including placebo.

A 49-person, 28-day placebo-controlled trial enrolled people with type 2 diabetes and painful neuropathy. ARA-290 improved HbA1c and lipid levels16, along with neuropathic symptoms. Beyond these ARA-290 neuropathy trials, most research on other organs has used animals and cells.

ARA-290 preclinical findings in animal and cell studies

In animal and cell studies, ARA-290 reduced tissue injury and inflammation across several organ systems.

Organ systemModelFinding
KidneyPigs with kidney blood-flow injuryBetter filtration, less scarring17 at day 7
KidneyHuman kidney cell lines exposed to cisplatinLess cell death and inflammation18
HeartAging rats, 15-month studyLess heart inflammation19, preserved heart function
BrainMice with ischemic strokeLess nerve-cell death20, dependent on the beta-common receptor
Brain and spinal cordRats with a multiple sclerosis modelMilder disease, less inflammation21
Peripheral nerveRats with autoimmune neuritisFaster recovery and nerve repair22
Gut and immune cellsMice with colitisLess inflammation, better survival23
SkinDiabetic mice with woundsBetter wound repair24
Transplanted isletsDiabetic mice, islets from matched donorsBetter blood sugar control25
Transplanted isletsDiabetic mice, islets from unmatched donorsDelayed graft loss26; longer graft survival with low-dose tacrolimus

These results record what happened in animals and cell cultures. They cannot show how ARA-290 acts in people, for whom it remains an unapproved compound.

ARA-290 FDA status as of November 2026

As of November 2026, ARA-290 (cibinetide) is not FDA-approved for any human use. FDA's 503A list of bulk substances nominated for pharmacy compounding places cibinetide in Category 3, for substances nominated without adequate support2.

ARA-290 has been granted orphan drug designation in the US27 and the European Union. The designation covers sarcoidosis and lowering the risk of graft loss in pancreatic islet transplantation.

Cibinetide is not among the six peptides in HHS's draft enforcement-discretion policy of October 30, 202628. That policy addresses pharmacy compounding of those six while FDA rulemaking continues. ARA-290's human safety record comes mostly from the same small Phase II trials.

ARA-290 safety in Phase II trials

In Phase II trials, ARA-290 showed no significant adverse effects3 in sarcoidosis. A type 2 diabetes trial recorded four serious adverse events in its ARA-290 group16. Two were judged possibly related to ARA-290. Long-term safety is unknown.

The 38-person sarcoidosis trial and the type 2 diabetes trial16 found no medically significant blood count or chemistry changes14. A 22-person pilot study found no safety concerns on laboratory testing29.

Reported ARA-290 side effects come mainly from trials lasting about four weeks. Researchers have called for longer dosing and follow-up3, so claims about ARA-290 deserve a careful read.

Where can I learn about peptides?

ARA-290 pairs broad animal research with a few small human trials and no FDA approval. A team of health journalists and licensed clinicians writes and fact-checks Superpower’s peptide library, keeping each level of evidence clearly labeled.

ARA-290 began as a slice of the much larger EPO molecule. The science behind peptides explains how a chain of 11 amino acids can act on its own.

IMPORTANT SAFETY INFORMATION

ARA-290 (cibinetide) is NOT FDA-approved for any indication. It is not legally marketed for human use. Superpower Health does not prescribe, sell, compound, or facilitate access to ARA-290.

Clinical safety data come mainly from small Phase II trials with short treatment durations. Longer-term safety has not been characterized. Hematological parameters were stable in reported trials, consistent with the compound's non-erythropoietic design.

ARA-290 should not be used by anyone outside an IRB-approved clinical research study. No FDA-approved indication exists, and no formal contraindications derived from an approved label exist because no label exists. Populations of particular concern based on mechanism and the absence of human data include: individuals with known or suspected malignancy (theoretical cell-survival signaling effects); pregnant or breastfeeding individuals (no reproductive or developmental toxicology data); individuals with severe renal impairment (uncharacterized pharmacokinetics); athletes subject to WADA-compliant testing; individuals taking anticoagulants or with coagulation disorders. These are illustrative concerns, not a contraindication checklist — there is no approved indication.

Products sold online as ARA-290 or cibinetide are unregulated. Their identity, purity, and dosing have not been verified by the FDA or any independent regulatory authority. There is no legal pharmaceutical-grade source for ARA-290 in the United States.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment guidance. Always consult a qualified healthcare provider before making any health decisions.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to ARA-290. ARA-290 is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science